JOP20240169A1 - عمليات تحضير عوامل انحلال مستقبلات الإستروجين الانتقائية - Google Patents
عمليات تحضير عوامل انحلال مستقبلات الإستروجين الانتقائيةInfo
- Publication number
- JOP20240169A1 JOP20240169A1 JOJO/P/2024/0169A JOP20240169A JOP20240169A1 JO P20240169 A1 JOP20240169 A1 JO P20240169A1 JO P20240169 A JOP20240169 A JO P20240169A JO P20240169 A1 JOP20240169 A1 JO P20240169A1
- Authority
- JO
- Jordan
- Prior art keywords
- estrogen receptor
- selective estrogen
- degrading agents
- preparation processes
- receptor degrading
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305520P | 2022-02-01 | 2022-02-01 | |
| US202263409060P | 2022-09-22 | 2022-09-22 | |
| PCT/US2023/011671 WO2023150056A1 (en) | 2022-02-01 | 2023-01-27 | Processes for the preparation of selective estrogen receptor degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240169A1 true JOP20240169A1 (ar) | 2024-07-30 |
Family
ID=85382684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0169A JOP20240169A1 (ar) | 2022-02-01 | 2024-07-30 | عمليات تحضير عوامل انحلال مستقبلات الإستروجين الانتقائية |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11926634B2 (https=) |
| EP (1) | EP4472982A1 (https=) |
| JP (3) | JP7387926B2 (https=) |
| KR (2) | KR20250006312A (https=) |
| AU (2) | AU2023216654B2 (https=) |
| CA (1) | CA3243621A1 (https=) |
| CO (1) | CO2024009411A2 (https=) |
| CR (1) | CR20240283A (https=) |
| DO (1) | DOP2024000150A (https=) |
| IL (1) | IL313886A (https=) |
| JO (1) | JOP20240169A1 (https=) |
| MX (1) | MX2024009453A (https=) |
| PE (1) | PE20241731A1 (https=) |
| TW (2) | TWI863110B (https=) |
| WO (1) | WO2023150056A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020137965A (ja) * | 2019-03-01 | 2020-09-03 | 株式会社三洋物産 | 遊技機 |
| US20240199629A1 (en) * | 2022-02-01 | 2024-06-20 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1709021B1 (en) | 2004-01-22 | 2010-08-04 | Eli Lilly And Company | Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
| US20080221163A1 (en) | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| EP2343287A1 (en) * | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| CN103582637B (zh) * | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸激酶抑制剂 |
| BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
| CN107406424B (zh) | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| MD3820874T2 (ro) | 2018-07-12 | 2023-05-31 | Lilly Co Eli | Degradanți selectivi ai receptorului estrogen |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| US11014915B2 (en) * | 2019-07-22 | 2021-05-25 | Sun Pharma Advanced Research Company Limited | Selective estrogen receptor degrader |
| CN115175679A (zh) | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗雌激素受体相关疾病的方法 |
| CN115867282B (zh) * | 2020-03-26 | 2025-05-27 | 奈克斯拉制药英国有限公司 | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| TWI837605B (zh) | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| TWI894443B (zh) | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2023
- 2023-01-27 EP EP23707540.3A patent/EP4472982A1/en active Pending
- 2023-01-27 PE PE2024001567A patent/PE20241731A1/es unknown
- 2023-01-27 WO PCT/US2023/011671 patent/WO2023150056A1/en not_active Ceased
- 2023-01-27 AU AU2023216654A patent/AU2023216654B2/en active Active
- 2023-01-27 CA CA3243621A patent/CA3243621A1/en active Pending
- 2023-01-27 MX MX2024009453A patent/MX2024009453A/es unknown
- 2023-01-27 CR CR20240283A patent/CR20240283A/es unknown
- 2023-01-27 KR KR1020247041076A patent/KR20250006312A/ko active Pending
- 2023-01-27 KR KR1020247028876A patent/KR102743629B1/ko active Active
- 2023-01-27 US US18/160,457 patent/US11926634B2/en active Active
- 2023-01-27 IL IL313886A patent/IL313886A/en unknown
- 2023-02-01 TW TW112103450A patent/TWI863110B/zh active
- 2023-02-01 TW TW113140271A patent/TW202523669A/zh unknown
- 2023-02-01 JP JP2023013779A patent/JP7387926B2/ja active Active
- 2023-08-28 JP JP2023138310A patent/JP7805336B2/ja active Active
-
2024
- 2024-07-16 CO CONC2024/0009411A patent/CO2024009411A2/es unknown
- 2024-07-30 JO JOJO/P/2024/0169A patent/JOP20240169A1/ar unknown
- 2024-07-31 DO DO2024000150A patent/DOP2024000150A/es unknown
-
2025
- 2025-09-04 JP JP2025146941A patent/JP2025183283A/ja active Pending
- 2025-09-16 AU AU2025234145A patent/AU2025234145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7387926B2 (ja) | 2023-11-28 |
| MX2024009453A (es) | 2024-08-09 |
| CA3243621A1 (en) | 2023-08-10 |
| EP4472982A1 (en) | 2024-12-11 |
| US11926634B2 (en) | 2024-03-12 |
| JP2023112696A (ja) | 2023-08-14 |
| KR102743629B1 (ko) | 2024-12-17 |
| AU2025234145A1 (en) | 2025-10-02 |
| KR20250006312A (ko) | 2025-01-10 |
| US20230242545A1 (en) | 2023-08-03 |
| DOP2024000150A (es) | 2024-08-30 |
| AU2023216654B2 (en) | 2025-09-25 |
| TWI863110B (zh) | 2024-11-21 |
| TW202523669A (zh) | 2025-06-16 |
| KR20240135862A (ko) | 2024-09-12 |
| CO2024009411A2 (es) | 2024-07-29 |
| JP2023162334A (ja) | 2023-11-08 |
| IL313886A (en) | 2024-08-01 |
| CR20240283A (es) | 2024-09-03 |
| WO2023150056A1 (en) | 2023-08-10 |
| JP7805336B2 (ja) | 2026-01-23 |
| TW202346300A (zh) | 2023-12-01 |
| PE20241731A1 (es) | 2024-08-19 |
| AU2023216654A1 (en) | 2024-07-11 |
| JP2025183283A (ja) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240169A1 (ar) | عمليات تحضير عوامل انحلال مستقبلات الإستروجين الانتقائية | |
| CR20240234A (es) | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) | |
| CY1110979T1 (el) | Παραγωγα κιναζολινης ως αναστολεις αγγειογενεσης και ενδιαμεσες ενωσεις αυτων | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| EP1489077A4 (en) | 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| PT2943493T (pt) | Compostos terapêuticos para o tratamento de infecções virais | |
| NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
| NO20085078L (no) | Nye forbindelser | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| US20220411438A1 (en) | Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) And Their Use In Therapy | |
| SA523442503B1 (ar) | مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها | |
| PY2228191A (es) | Nuevos derivados de heteroaril aminopropanol | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| NO20062491L (no) | Benzoksazinderivter og deres anvendelse | |
| NO952289L (no) | Substituerte benzazepinoner | |
| UY28688A1 (es) | Derivados de amida | |
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| NO20074622L (no) | Metabolitter for NK-1 antagonister for brekninger | |
| DK1412332T3 (da) | Quinolinderivater og anvendelse deraf som antitumormidler | |
| WO2004066952A3 (en) | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | |
| MX2025007158A (es) | Inhibidores de gmp?amp sintasa ciclica y sus usos | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |